spot_img
Wednesday, November 18, 2026

Nokia Bell Labs spin-out AstraNu raises $3.5M seed round backed by Celesta Capital and NJEDA

AstraNu, a Murray Hill-based developer of chip-scale optical imaging engines for the medical device industry, has closed a $3.5 million seed funding round led by deep-tech venture firm Celesta Capital, with co-investment from the New Jersey Economic Development Authority’s (NJEDA) New Jersey Innovation Evergreen Fund (NJIEF).

Spun out of Nokia Bell Labs in May 2025 as the inaugural venture under a strategic commercialization partnership between Nokia and Celesta Capital, AstraNu has developed a chip-scale swept-source optical coherence tomography (SS-OCT) engine. The company will deploy the new capital to expand its photonics engineering team, validate engine performance in partner testbeds, and prepare for volume manufacturing.

“This funding enables us to drive our strategy forward by building out our photonics development team and manufacturing readiness ahead of customer volume,” Kevin Blalock, president and general manager of AstraNu, said in a press release. “Celesta’s backing, together with the NJIEF’s support, gives us the runway to get our engine into partner testbeds and validate the performance we have achieved.”

While swept-source OCT provides faster and deeper tissue imaging than legacy spectral-domain OCT (SD-OCT) systems, its adoption across medical devices has historically been constrained by equipment size and component costs.

Originally developed at Nokia Bell Labs, AstraNu’s integrated module shrinks SS-OCT hardware onto a single chip that is more than 10 times smaller than conventional systems—delivering swept-source imaging performance at spectral-domain price points.

AstraNu supplies its imaging engine as an embedded component for established medical device, imaging, and optics manufacturers. Ophthalmology—currently the largest commercial market for OCT diagnostics—serves as the company’s initial target sector, alongside active application development in ear, nose, and throat (ENT) care, urology, and oncology.

For Celesta Capital and the state-backed NJIEF—which matched Celesta’s investment following NJEDA board approval last month—the deal underscores an ongoing push to commercialize New Jersey research-lab intellectual property into scalable hardware businesses.

“AstraNu is an outstanding example of where we invest: foundational technology from one of the world’s leading research labs, with the potential to change what is possible in a large and established market,” Matthew Marsh, managing partner and CFO at Celesta Capital said. “Scaling a technology like this from the lab into volume production requires disciplined operations and commercial partners – supporting founders in this work is what we do. Celesta is delighted to lead this round alongside NJEDA, and to continue our partnership with Nokia to build globally competitive companies around market-shifting technologies.”

Medical device, imaging, and optics manufacturers seeking to evaluate the imaging module can contact AstraNu at [email protected].

+ posts

Get the Latest News

Sign up to get all the latest news, offers and special announcements.

Get our Print Edition

All the latest updates, delivered.

Latest Posts

Get the Latest News

Sign up to get all the latest news, offers and special announcements.

Get our Print Edition

All the latest updates, delivered.